5,421
edits
P2Y12 inhibitors: Difference between revisions
no edit summary
(Created page with "'''P2Y<sub>12</sub> inhibitors''' are antiplatelet drugs. They are are often used in combination with acetylsalicylic acid, which is called ''dual antiplatelet therapy'' (<abbr>DAPT</abbr>). However, they may also be used alone. == Compounds == * Clopidogrel (Plavix®) * Prasugrel (Efient®) * Ticagrelor (Brilique®) == Mechanism of action == These drugs inhibit the P2Y12 receptor, an ADP receptor which is found on platelets. This receptor binds ADP which is r...") |
No edit summary |
||
| Line 1: | Line 1: | ||
'''P2Y<sub>12</sub> inhibitors''' are [[antiplatelet drugs]]. They are are often used in combination with [[acetylsalicylic acid]], which is called ''dual antiplatelet therapy'' (<abbr>DAPT</abbr>). However, they may also be used alone. | <section begin="clinical biochemistry" />'''P2Y<sub>12</sub> inhibitors''' are [[antiplatelet drugs]]. They are are often used in combination with [[acetylsalicylic acid]], which is called ''dual antiplatelet therapy'' (<abbr>DAPT</abbr>). However, they may also be used alone.<section end="clinical biochemistry" /> | ||
== Compounds == | == Compounds == | ||
* Clopidogrel (Plavix®) | * Clopidogrel (Plavix®) | ||
* Prasugrel (Efient®) | * Prasugrel (Efient®) | ||
| Line 12: | Line 11: | ||
== Pharmacokinetics == | == Pharmacokinetics == | ||
Clopidogrel and prasugrel are irreversible inhibitors, while ticagrelor is a reversible inhibitor. They have similar half-lives but the effect lasts longer for the irreversible inhibitors, as new platelets must be formed for the effect to pass. | Clopidogrel and prasugrel are irreversible inhibitors, while ticagrelor is a reversible inhibitor. They have similar half-lives but the effect lasts longer for the irreversible inhibitors, as new platelets must be formed for the effect to pass. | ||
<noinclude>[[Category:Pharmacology]] | |||
== Monitoring == | |||
<section begin="clinical biochemistry" />One can monitor P2Y<sub>12</sub> therapeutic effect with [[platelet aggregometry]] with ADP, but this is not routinely performed. There are no known uses for this, as a therapeutic reference range has not been established.<section end="clinical biochemistry" /><noinclude> | |||
[[Category:Pharmacology]] | |||
</noinclude> | </noinclude> | ||